Acasă › Leucemie mieloasă acută › Connecticut
Studii clinice pentru Leucemie mieloasă acută în Connecticut
17 studii pentru Leucemie mieloasă acută caută participanți în Connecticut.
Orașe în Connecticut
Text oficial al studiului (în engleză)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 22 sept. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
În curs de recrutareFaza 3
6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Yale University, New Haven
În curs de recrutareFaza 3
29 Days – 21 Years · Toate sexele · Actualizat 24 aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
În curs de recrutareStudiu observațional
Toate vârstele · Toate sexele · Actualizat 6 iul. 2026 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Yale New Haven Hospital, New Haven
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 15 iun. 2026 · NCT05768932A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 apr. 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
În curs de recrutareFaza 1
Vârste de la 18 la 75 · Toate sexele · Actualizat 25 mar. 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 mar. 2026 · NCT05735184Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Yale University, New Haven
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 26 aug. 2025 · NCT03850574Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.